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A B S T R A C T
The traditional biomarkers, CK-MB and troponins, used for the diagnosis of myo-
cardial ischemia and the risk stratification of patients with acute coronary syndromes 
(ACS) are of limited use mainly because they require some degree of necrosis in order 
to become detectable. Based on the knowledge gained into the pathophysiology of 
ACS, several new biomarkers have been developed. Brain natriuretic peptides (BNP 
and NT-proBNP) as markers of hemodynamic stress have shown in several studies 
a good diagnostic and prognostic performance. C-reactive protein (CRP) reflecting 
systemic inflammation, has mainly a role as risk stratifier. Ischemia modified albumin 
(IMA) a pure ischemia marker may offer a substantial aid in diagnosing an acute 
coronary event in patients with negative troponin. Finally, myeloperoxidase (MPO), a 
marker of oxidative stress, may also contribute to the diagnosis of ischemia although 
this is not yet supported by a fair amount of data. Nevertheless, although highly sen-
sitive, these new biomarkers are not specific enough and a multi-marker approach 
seems the most appropriate strategy for diagnosis of myocardial ischemia and for as-
sessing the risk of an adverse outcome in patients with an acute coronary syndrome.
I N T R O D U C T I O N
Establishing a diagnosis of myocardial ischemia in the clinical setting remains a 
challenging task. In addition to history of chest pain and abnormal electrocardiographic 
(ECG) changes, laboratory evidence of myonecrosis has always been an integral part 
of the initial diagnostic work up of a suspected acute coronary syndrome (ACS).1 
Unfortunately, the myonecrosis markers, myoglobin, creatine kinase (CK-MB) and 
the troponins (Tns), cannot by definition help clinicians in the assessment of patients 
with stable or unstable angina where ischemia is not accompanied most of the time 
by myocardial necrosis. In addition, myocardial necrosis is time-dependent, such that 
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these highly sensitive and specific markers might give negative 
results on admission but give positive results hours later.2 As 
such, the usefulness of the conventional biomarkers of myo-
cardial necrosis for the confident exclusion of the diagnosis of 
myocardial ischemia at the time of admission remains limited. 
Markers able to identify patients with myocardial ischemia 
without infarction might play an important role in the clini-
cal setting since among those patients with a definite ACS, 
early treatment may reduce the extent of myocardial injury, 
and thus rapid diagnosis and initiation of therapy is a central 
tenet of management.3 In addition, given the increasing array 
of treatments for the heterogeneous population of patients 
admitted with ACS, effective risk stratification and targeting 
of therapy have become a focus of contemporary manage-
ment of clinically evident myocardial ischemia.4 As such, the 
objectives of the initial assessment are twofold: (a) to assess 
the probability that the patient’s symptoms are related to acute 
coronary ischemia (i.e. establish the diagnosis) and (b) to 
assess the patient’s risk of recurrent cardiac events, including 
death and recurrent ischemia (define the prognosis). In this 
review, the role of some newly developed biochemical mark-
ers in establishing the diagnosis and prognosis of myocardial 
ischemia will be briefly presented.
B R A I N  N A T R I U R E T I C  P E P T I D E S  ( B N P )
The brain natriuretic peptide (BNP) is synthesized by 
cardiac myocytes when left ventricular wall stress increases.5 
After secretion, the pro-hormone is cleaved to the biologi-
cally active hormone (BNP) and to the inactive N-terminal 
fragment (NT-proBNP). Enough evidence already exists that 
measuring the blood level of either one of these molecules 
improves the ability to diagnose or exclude heart failure as 
the cause of acute dyspnea.6,7 Moreover, BNP measurement 
provides useful prognostic information on mortality risk in 
patients with heart failure.8,9 However, only recently BNP 
has also been recognized as a potential diagnostic marker of 
myocardial ischemia as well as a prognostic indicator in pa-
tients with coronary artery disease. Jernberg et al10 collected 
blood samples of 775 acute chest pain patients without ST-
segment elevation upon admission to the coronary care unit 
and showed that patients with an acute myocardial infarction 
(MI) had significantly higher median BNP levels than patients 
with unstable angina or non-cardiac chest pain. Bassan et al11 
studied prospectively 631 patients presenting to the emergency 
department with chest pain and without ST-elevation in the 
ECG. Sensitivity of admission BNP for acute MI (cut off value 
of 100 pg/ml) was significantly higher than CPK-MB and TnI 
(70.8% vs. 45.8% vs. 50.7% respectively). However, specificity 
was substantially lower (~70% vs. ~98%). Simultaneous use of 
all 3 markers significantly improved sensitivity to 87.3% and 
negative predictive value to 97.3%. According to these data, 
the use of natriuretic peptides in the emergency department as 
a simple aid for deciding whether a chest-pain patient should 
be admitted to the hospital or can safely be discharged home 
seems very promising. Nevertheless, this marker needs to 
be more thoroughly investigated before being accepted as a 
clinically useful tool.
On the other hand, more research has been conducted 
regarding the prognostic role of natriuretic peptides in the 
setting of acute or chronic myocardial ischemia. Levels of BNP 
and NT-proBNP have shown to correlate with left ventricular 
dilatation, remodeling, and dysfunction, as well as congestive 
heart failure and death among patients presenting with acute 
MI.12 Beyond that, several studies have now demonstrated 
a robust association between BNP or NT-proBNP and the 
short- and long-term risk of death across the spectrum of 
non-ST-elevation ACS including patients without myocardial 
necrosis or clinical evidence of heart failure. In the most recent 
of those studies, Jarai et al13 showed that Nt-proBNP along 
with TnI were independent predictors of 2-year mortality in 
120 patients with unstable angina. These findings confirmed 
the results of previous studies which had similarly shown that 
both BNP and NT- proBNP offered significant information 
about short and long term prognosis in patients with unstable 
angina and that this information was independent of the left 
ventricular systolic function.14-17
Finally, another very interesting emerging concept is that 
natriuretic peptides may have a prognostic role not only in the 
acute ischemia setting but also in patients with chronic isch-
emic heart disease. Thus, Ndrepepa et al18 recently published 
the results of their study which included 1059 patients with 
chronic stable angina. NT-proBNP levels were the strongest 
correlate of 5-year mortality in this population outweigh-
ing other significant variables like age, New York Heart 
Association (NYHA) class and CRP. In this study, plasma 
NT-proBNP enabled the identification of a group of patients 
who were at particularly high risk for death after coronary 
intervention with stenting. Similar findings were reported 
by the AtheroGene study investigators who prospectively 
followed 904 patients with stable and unstable angina for 2 
years.19 Baseline NT-proBNP was significantly higher among 
individuals with cardiovascular events compared with those 
without events. In the subgroup of patients with stable an-
gina, those within the top quartile had a 3.7-fold increase in 
cardiovascular risk. To further expand the prognostic role of 
natriuretic peptides even in patients with disease in other than 
the coronaries vascular beds, Campbell et al20 showed that 
NT-proBNP levels were able to predict MI in subjects who 
had experienced a cerebrovascular event. In this nested case-
control study which was part of the Perindropril Protection 
Against Recurrent Stroke Study (PROGRESS), NT-proBNP 
was found superior to CRP and to renin levels in predict-
ing cardiovascular risk. The mechanism responsible for the 
increased levels of brain natriuretic peptides in myocardial 
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ischemia remains unclear. Increased ventricular wall stress 
due to ischemia induced systolic or diastolic dysfunction cer-
tainly plays a role. Indeed, Richards et al21 recently showed 
that both BNP and NT-proBNP closely correlated with left 
ventricular ejection fraction in a large population with stable 
ischemic heart disease being at the same time independent 
predictors of 12-month total mortality and admission to the 
hospital with heart failure. However, evidence also exists 
that ischemia may itself promote BNP gene expression in the 
hypoxic myocardium of the left ventricle.22
C - R E A C T I V E  P R O T E I N
C-reactive protein (CRP) is the inflammatory marker 
receiving the most attention to date as a prognostic indicator 
of coronary artery disease. It is an acute phase reactant nor-
mally present in plasma at low levels, and increases >100-fold 
in response to inflammatory stimuli. It is produced by hepa-
tocytes in response to stimulation by interleukin-6. It is also 
produced by human coronary artery smooth muscle cells.23 
Although initially considered only a marker of inflammation, 
CRP itself has been shown to possess pro-inflammatory and 
pro-atherogenic properties. It stimulates endothelial cells to 
express adhesion molecules and secrete cytokines24,25 and it 
decreases the expression of endothelial NO synthase.26,27 CRP 
accumulates in macrophage-rich regions of nascent athero-
sclerotic lesions and activates the macrophages to express cy-
tokines and tissue factor, while enhancing macrophage uptake 
of LDL.28 It also amplifies pro-inflammatory effects of several 
other mediators including endotoxin.29,30 In a post-mortem 
study of 302 autopsies of men and women with atherosclerosis, 
median CRP levels were higher with acute plaque rupture 
than in stable plaques or controls.31 The levels correlated with 
the staining intensity for CRP in macrophages and the lipid 
core of plaques, and it increased with the number of thin cap 
atheromas found in coronary arteries. Plasma CRP levels at 
the upper end of the reference range in apparently healthy men 
and women, in the absence of other sources of inflammation, 
correlated with increased risk of future cardiovascular events, 
including MI, peripheral vascular disease with intermittent 
claudication and stroke32. These data support the view that 
systemic CRP accurately reflects the number of vulnerable 
atherosclerotic plaques. A decade ago Liuzzo et al33 reported 
that patients with unstable angina and elevated levels of CRP 
(> 3 mg/dl) had higher rates of death, acute MI and need 
for revascularization compared to patients without elevated 
levels. Moreover, this increased risk may be evident as early 
as 14 days after presentation.34 These findings have been con-
firmed by more recent data. The CAPTURE trial found that 
although only TnT was predictive in the first 72-hour period, 
both CRP and TnT were predictors of risk within 6 months.35 
The FRISC Investigators reported that the risk associated 
with elevated CRP levels at the time of an index ACS event 
continued to increase for several years afterwards.36 Mueller et 
al37 reported that in ACS patients who were treated with very 
early revascularization, CRP was a strong independent predic-
tor of both short-term and long-term mortality. However, not 
everybody agrees that CRP levels are of significant prognostic 
importance. Lee et al38 recently showed that CRP did fairly 
worse compared to interleukin-6 and total homocystein in 
predicting coronary artery disease related death in a cohort 
of 1117 consecutive patients undergoing selective coronary 
angiography. Nevertheless, most of the experts in the field 
seem to agree that the role of CRP as a prognostic marker in 
patients with an ACS appears to be established.
Unfortunately, despite its prognostic importance, the 
contribution of CRP to the diagnosis of coronary ischemia is 
rather poor. This has been confirmed by a recently published 
systemic review of the potential use of 22 protein markers in 
low risk patients presented to the emergency department with 
chest pain. CRP demonstrated an area under the curve of only 
0.61 in the summary receiver operator characteristic (ROC) 
curve analysis with a pooled diagnostic odds ratio of 1.81.39 
This has to be attributed to the very low specificity of this 
biomarker. Daily fluctuations in basal CRP levels are signifi-
cant and are 4–6 times greater than cholesterol fluctuations. 
CRP levels are transiently elevated for 2–3 weeks following a 
major infection or trauma. Chronic inflammatory conditions 
like rheumatoid arthritis or lupus will also confuse interpreta-
tion of CRP levels. Minor inflammatory stimuli, such as viral 
infection, skin lacerations and some noninflammatory states 
(e.g., a low level of physical activity, aging, chronic fatigue, 
high protein diets, alcohol consumption and depression), are 
also known to influence CRP. These limitations make the 
CRP practically useless in differentiating among patients with 
chest pain those who have myocardial ischemia. Moreover, 
knowledge of these other causes of CRP fluctuations can help 
interpret its value for cardiovascular risk assessment as well.
I S C H E M I A  M O D I F I E D  A L B U M I N  ( I M A )
Ischemia modified albumin (IMA) is a new marker of tran-
sient myocardial ischemia. IMA is measured by the Albumin 
Cobalt Binding (ACB) test, which measures the binding capac-
ity of exogenous cobalt to the N-terminus of human albumin. 
In the presence of myocardial ischemia, structural changes 
take place in the N-terminus of albumin that rapidly reduce 
its binding capacity for transition metal ions. These changes 
in the N-terminus of human albumin are attributed, among 
other factors, to ischemia/reperfusion mediators, hypoxia, and 
acidosis. There is no correlation between the ACB test results 
and human serum albumin levels in normal range. Studies 
have shown that IMA is highly sensitive for the identification 
of ACS and, in combination with the ECG and troponin, has 
124
HOSPITAL CHRONICLES 3(3), 2008
both high sensitivity and negative predictive value. IMA has 
also been shown to be elevated in patients after coronary 
angioplasty as a result of ischemia reperfusion injury.
Unlike troponin (a marker of ongoing myocardial injury), 
IMA is a marker of impending myocyte necrosis. During 
ischemia, free-radical damage alters the ability of albumin to 
bind cobalt. Using a colour indicator (dithiotreitol) to detect 
added cobalt, the level of such altered albumin in serum can 
be quantitated.40 IMA has been shown to rise within minutes 
after the onset of ischemia, stay elevated for 6 to 12 hours, and 
return to normal within 24 hours. Furthermore, IMA has been 
shown to predict with high sensitivity subsequent elevation 
in the Tns in the clinical setting.41 Blood levels of IMA rise 
in patients who develop ischemia during percutaneous coro-
nary intervention42,43. IMA levels during balloon angioplasty 
are related to number, pressure, and duration of inflations, 
suggesting that IMA reflects the magnitude and duration of 
ischemia induced during percutaneous coronary intervention 
and is not simply a marker of free radical damage.
Moreover, according to recent studies, IMA has twice 
the sensitivity of an ECG and four times the sensitivity of 
troponin to detect patients with ACS at time of presentation; 
this is particularly evident in those patients with unstable 
angina, which is difficult to diagnose with other diagnostic 
methods. Sinha et al.44 evaluated IMA in conjunction with 
ECG changes and cardiac TnT levels in 208 patients present-
ing to the emergency department within 3 hours of the onset 
of acute chest pain. In the whole patient group, sensitivity of 
IMA at presentation for an ischemic origin of chest pain was 
82%, compared with 45% of ECG and 20% of TnT. IMA 
used together with troponin T or ECG, had a sensitivity of 
90% and 92%, respectively. Similarly, Roy et al 45 showed 
that in 131 patients presenting to the emergency department 
with symptoms suggestive of acute myocardial ischemia but 
with normal or non-diagnostic ECGs, IMA levels >93.5 U/
ml demonstrated a sensitivity and specificity of 75% for the 
diagnosis of ACS with an area under the ROC curve 0.78. 
Moreover, in combination with cardiac TnT levels >0.05 
ng/ml, the sensitivity increased to 92.2%. These findings were 
confirmed by the recently published results of Anwaruddin 
et al46 who measured IMA along with standard biomarkers 
(myoglobin, CK-MB and TnI) in 200 patients with suspected 
myocardial ischemia admitted to the emergency department. 
In this patient population, the myoglobin–CK-MB–TnI triad 
had a sensitivity of 57% for detecting myocardial ischemia. 
The combination of IMA–myoglobin–CK-MB–TnI increased 
the sensitivity for detecting ischemia to 97%, with a negative 
predictive value of 92%. It should be noted however, that 
IMA alone was somewhat poorly specific for the presence of 
ischemia (specificity: 31%). Given its high negative predictive 
value as supported by the current evidence, the test has been 
approved by the FDA as a “rule-out” marker of myocardial 
ischemia. But some questions about how timing affects its 
performance also persist.47 The change to albumin binding oc-
curs very quickly but it also seems to disappear quickly (within 
2-3 hours of the ischemic event). The exact mechanism of the 
initial alteration in cobalt binding and the reason for its rapid 
disappearance is unknown. This limits IMA’s usefulness as 
an additional marker in patients whose Tn level is only slightly 
elevated using the 99th percentile cut-off (and, therefore, pos-
sibly a false positive). If myocardial ischemia was the cause of 
the slight Tn elevation, IMA probably would have normalized 
by the time that Tn was elevated. Also, IMA may be falsely 
elevated (as far as myocardial ischemia is concerned) due to 
ischemia in other parts of the body.48
Finally, the use of IMA as a risk stratifier in patients with 
acute or chronic ischemia has not been extensively evaluated. 
In the only study published so far, IMA was a poor predic-
tor of serious cardiac outcomes in short term (72 hours of 
follow-up).49 Nevertheless, this was a rather small study of 
189 patients and for a definite answer about the prognostic 
role of this new biomarker, further evaluation in larger trials 
seems necessary.
M Y E L O P E R O X I D A S E  ( M P O )
First identified within human atherosclerotic plaque nearly 
a decade ago,50 myeloperoxidase (MPO) has emerged as an 
important potential participant in the atherosclerotic process. 
MPO, a member of the heme peroxidase superfamily, gener-
ates reactive oxidants and diffusible radical species as part of 
its normal function in innate host defenses.51 A unique activity 
of MPO is its ability to use the halide chloride as co-substrate 
with hydrogen peroxide to generate chlorinating oxidants such 
as hypochlorous acid (HOCl), a potent bactericidal agent.52 
MPO, and specific chlorinated protein and lipid oxidation 
products, are all markedly enriched within human atheroma. 
Leukocytes use MPO to generate oxidants capable of initiat-
ing lipid peroxidation53 including conversion of LDL into an 
atherogenic form recognized by macrophage scavenger recep-
tors54. MPO may also contribute to the atherosclerotic process 
by promoting endothelial dysfunction, by virtue of its capacity 
to catalytically consume nitric oxide as a substrate in vitro55 
and in vivo,56 resulting in formation of nitric oxide–derived 
oxidants.57
Indeed, recent clinical studies demonstrate that systemic 
levels of MPO serve as a strong and independent predictor of 
endothelial dysfunction in subjects,58 as well as angiographic 
evidence of coronary artery disease.59 Finally, recent human 
genetic studies support a potential role for MPO in coronary 
artery disease because MPO deficiency in subjects is report-
edly cardioprotective,60 and individuals possessing a func-
tional polymorphism associated with approximately two-fold 
decrease in MPO expression have reduced cardiac risks.61,62 
Given the increasing volume of pre-clinical and clinical data 
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about the association of this enzyme with oxidation, athero-
genesis and possibly plaque rupture, clinical trials have been 
initiated to assess its validity as a diagnostic and prognostic 
marker of myocardial ischemia.
In a landmark study, Brennan et al63 measured baseline 
levels of MPO, troponin T, and CRP in 604 chest-pain patients. 
To establish normal MPO levels, researchers also obtained 
measurements from 115 healthy volunteers without coronary 
artery disease. MPO levels were higher in patients who had an 
MI within 16 hours after presentation than in patients who did 
not. An elevated level predicted risk even in patients with nor-
mal initial troponin levels and irrespective of the time between 
symptom onset and presentation. The risk increased with 
increasing quartiles of MPO level. Most important, elevated 
levels at presentation predicted the risk for major coronary 
events at 30 days and at 6 months. The adjusted odds ratio 
for patients in the highest quartile compared with patients in 
the lowest quartile was 4.7. MPO was found to be a stronger 
predictor than CRP. Last year, based mainly on the results of 
this study, FDA approved an enzyme-linked immunosorbent 
assay (CardioMPO) for the quantitative determination of 
MPO in human plasma. However, the general feeling of the 
medical community is that further studies are needed to gain 
more insight into the quantity and quality of information of-
fered by this very promising new biomarker.
C O N C L U S I O N S
Acute coronary syndrome (ACS) is the final step of a 
complex pathophysiologic process including 1) progres-
sive mechanical obstruction due to atheroma formation, 
2) dynamic obstruction due to vasoconstriction, 3) plaque 
rupture with acute thrombosis as a consequence of oxidative 
stress and inflammation, 4) cardiac myocyte ischemia and 
necrosis, and 5) hemodynamic and ventricular wall stress. 
The better understanding of this whole process has led to 
the emergence of novel, sensitive biomarkers representing all 
the above pathophysiologic steps (Figure 1). There is grow-
ing evidence that these markers may become valuable for 
the diagnosis of ischemia and for assessing the risk of short 
and long term adverse outcome in patients presenting to 
the emergency department and to the outpatient clinic with 
symptoms suggestive of an ACS. However, these patients may 
vary substantially with respect to the relative contribution of 
each pathophysiologic step in the individual clinical picture. 
Accordingly, the relative importance of each biomarker may 
also vary in different patients. Moreover, both old and new 
biomarkers, although sensitive, lack the specificity needed 
to gain widespread clinical application as a single marker of 
disease. Thus, a multi-marker strategy employing a patho-
physiologically diverse set of biomarkers seems the most ap-
propriate to lead ultimately to the best therapeutic strategy for 
the individual patient.64 Nevertheless, further work needs to 
be done to define the optimal weighing of each biomarker for 
diagnosis and prognosis of myocardial ischemia and to assess 
the appropriate therapeutic responses to different patterns of 
biomarker elevation in ACS.
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